Cargando…

Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves’ Orbitopathy

Detalles Bibliográficos
Autores principales:	George, Augustine, Diana, Tanja, Längericht, Jan, Kahaly, George J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885640/ https://www.ncbi.nlm.nih.gov/pubmed/33603715 http://dx.doi.org/10.3389/fendo.2020.629925

Ejemplares similares

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application
por: Längericht, Jan, et al.
Publicado: (2020)

Sensitivity of three thyrotropin receptor antibody assays in thyroid-associated orbitopathy
por: Sarić-Matutinović, Marija, et al.
Publicado: (2022)

Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease
por: Kahaly, George J, et al.
Publicado: (2019)

Thyrotropin Receptor Blocking Antibodies
por: Diana, Tanja, et al.
Publicado: (2018)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

SAT-557 Functional Thyrotropin Receptor Antibodies Confirm a Novel Graves' Disease Animal Model
por: Diana, Tanja, et al.
Publicado: (2019)

FRI540 A Novel, Rapid, Sensitive Bioassay For Thyrotropin Receptor Stimulatory Antibodies Improves Diagnosis & Management Of Autoimmune Thyroid Disease
por: Jean Kahaly, George, et al.
Publicado: (2023)

SAT-429 Systemic Safety Analysis of Mycophenolate in Graves’ Orbitopathy
por: Lee, Alan C H, et al.
Publicado: (2020)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

TSH Receptor Antibody Functionality and Nomenclature
por: Kahaly, George J., et al.
Publicado: (2017)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves’ orbitopathy
por: Park, Jungyul, et al.
Publicado: (2023)

Thyrotropin Receptor Epitope and Human Leukocyte Antigen in Graves’ Disease
por: Inaba, Hidefumi, et al.
Publicado: (2016)

MON-583 Functional Thyrotropin Receptor Antibodies in Pregnant Women with Thyroid Autoimmunity
por: Diana, Tanja, et al.
Publicado: (2019)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Cut-Off Value of Thyrotropin-Receptor Antibodies in Grave’s Disease in Basrah
por: Radhi, Maher A, et al.
Publicado: (2023)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

FRI537 Thyrotropin Receptor Blocking Antibodies - A Multicenter, 4-Assay Comparison
por: George, Augustine, et al.
Publicado: (2023)

Not All Orbitopathy Is Graves’: Discussion of Cases and Review of Literature
por: Boddu, Neeraja, et al.
Publicado: (2017)

Therapeutic Potential of Targeting Periostin in the Treatment of Graves’ Orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2022)

Editorial: News in Graves’ orbitopathy: patients management and treatments
por: Lanzolla, Giulia, et al.
Publicado: (2023)

OR18-03 Functional TSH Receptor Antibodies Are a Biomarker for Graves’ Disease - a Prospective Trial
por: Kahaly, George Jean, et al.
Publicado: (2020)

SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
por: Kahaly, George, et al.
Publicado: (2019)

Reply to Drs. Kiaei and Molinaro Regarding the Publication “Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation”
por: Allelein, Stephanie, et al.
Publicado: (2020)

OR26-01 A Novel Small Molecule Thyrotropin Receptor Antagonist
por: Kahaly, George Jean, et al.
Publicado: (2023)

Immunological Features of Paranasal Sinus Mucosa in Patients with Graves’ Orbitopathy
por: Lu, Yi, et al.
Publicado: (2021)

Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2020)

Editorial: Mechanisms and Novel Therapies in Graves’ Orbitopathy: Current Update
por: Zhou, Huifang, et al.
Publicado: (2022)

ELF3-induced miR-182 inhibits adipogenic differentiation in Graves’ orbitopathy by targeting thyrotropin receptor
por: Wang, Sha, et al.
Publicado: (2023)

Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients
por: Villagelin, Danilo, et al.
Publicado: (2019)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Thyroid-Stimulatory Antibody as a Predictive Factor for Graves’ Disease Relapse
por: Da Silva Santos, Tiago, et al.
Publicado: (2022)

Thyroid eye disease or Graves’ orbitopathy: What name to use, and why it matters
por: Wagner, Lilly H., et al.
Publicado: (2022)

High IgG4 serum concentration is associated with active Graves orbitopathy
por: Olejarz, Michał, et al.
Publicado: (2023)

Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves’ orbitopathy: an observational study
por: Boutzios, Georgios, et al.
Publicado: (2023)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Commentary: Brief report - Monoclonal antibodies illustrate the difficulties in measuring blocking TSH receptor antibodies
por: Olivo, Paul D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f6oorb61fbkbqs30jqqih6i7dt